US EditionDax only Short Term over 24,000 Points – Biontech & Gerresheimer
Summary by finanzen100.de
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Which investments are currently in the shop window? What moves the markets? Which companies and heads are taking courses and what action is required for your depot? In our market compass, we deal today with the following topics: Biontech with Megadeal +++ Gerresheimer under pressure +++ Success for Novartis.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
